Your shopping cart is currently empty

A-385358 is a selective Bcl-xL inhibitor with Kis of 0.80 nM for Bcl-xL and 67 nM for Bcl-2, respectively.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $55 | In Stock | In Stock | |
| 5 mg | $117 | In Stock | In Stock | |
| 10 mg | $177 | In Stock | In Stock | |
| 25 mg | $297 | In Stock | In Stock | |
| 50 mg | $445 | In Stock | In Stock | |
| 100 mg | $630 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $169 | In Stock | In Stock |
| Description | A-385358 is a selective Bcl-xL inhibitor with Kis of 0.80 nM for Bcl-xL and 67 nM for Bcl-2, respectively. |
| Targets&IC50 | Bcl-2:67 nM (ki), BCL-XL:0.8 nM (ki) |
| In vitro | In IL-3-deprived FL5.12/Bcl-XL cells, A-385358 results in cell killing with an EC50 of 0.47 μM and increases caspase-3 activity. The EC50 of A-385358 for IL-3-depleted FL5.12/Bcl-2 cells with an EC50 of 1.9 μM which is 4-fold higher relative to the cytokine-deprived FL5.12/Bcl-XL cells. A-385358 stimulates more cytochrome c release from mitochondria isolated from FL5.12/Bcl-XL versus Bcl-2 cells[1]. |
| In vivo | The combination of A-385358 (75 mg/kg) plus paclitaxel (30 mg/kg) is well tolerated and inhibits tumor growth rate by nearly 80%. A-385358 exhibits slow but steady increase in the tumor growth. The combination of A-385358 (100 mg/kg) and a lower dose of paclitaxel produces a significant reduction in tumor growth and yields a >100% increase in time for tumors to reach 900 mm3 (%ILS)[1]. |
| Molecular Weight | 639.83 |
| Formula | C32H41N5O5S2 |
| Cas No. | 406228-55-5 |
| Smiles | CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCC(C)(C)CC1 |
| Relative Density. | 1.31 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (70.33 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Saline: 2 mg/mL (3.13 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.